サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：スタチンの世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 薬剤クラス別、治療法別、エンドユーザー別、地域別
市場調査レポート
商品コード
1410564

スタチンの世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 薬剤クラス別、治療法別、エンドユーザー別、地域別

Statins Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
出版日: | 発行: Fairfield Market Research | ページ情報: 英文 250 Pages | 納期: 2～5営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
スタチンの世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 薬剤クラス別、治療法別、エンドユーザー別、地域別
出版日: 2024年01月09日
発行: Fairfield Market Research
ページ情報: 英文 250 Pages
納期: 2～5営業日
  • 全表示
  • 概要
  • 目次
概要

世界のスタチンの市場規模は着実な成長軌道にあり、2024年には154億米ドル、2031年には210億米ドルに達すると予測されています。

スタチンに対する世界の需要は、世界の高コレステロールおよび肥満の罹患率の増加によって大きな影響を受けています。ライフスタイルの変化と座りがちな生活習慣が高コレステロール値の上昇につながっており、スタチンはコレステロール管理に不可欠なソリューションとなっています。

スタチンは、生活習慣の改善だけではコントロールが困難な高コレステロール値に対処する上で重要な役割を果たしています。さらに、意識向上への取り組みや先進ヘルスケア施設がスタチン需要の拡大に寄与しています。

さらに、エゼチミブのような他のコレステロール低下薬とともにスタチンを含む併用療法の採用が、世界市場をさらに牽引すると予想されます。スタチンとエゼチミブの併用療法は、ほぼ正常な脂質プロファイルを達成し、心血管疾患のリスクを低減することが期待されています。

スタチン市場は成長態勢にあるもの、主に製造コストの高さと製造プロセスの複雑さに関連する課題は依然として残っています。さらに、厳密な分析特性評価と規制当局の承認手続きを通じてバイオシミラー性を確立することは、依然として時間とコストのかかるプロセスです。

しかし、研究開発への投資の増加、ヘルスケア施設の改善への強い関心、官民間の戦略的協力関係は、スタチンメーカーに成長機会をもたらすと期待されています。

当レポートでは、世界のスタチン市場について調査し、市場の概要とともに、薬剤クラス別、治療法別、エンドユーザー別、地域別動向、および市場に参入する企業の競合動向などを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の定義とセグメンテーション
  • 市場力学
  • バリューチェーン分析
  • ポーターのファイブフォース分析
  • COVID-19の影響分析
  • ウクライナとロシアの紛争の影響
  • 経済概要
  • PESTLE分析

第3章 生産高と貿易統計、2018年～2023年

第4章 価格分析、2018年～2023年

第5章 世界のスタチン市場の見通し、2018年～2031年

  • 世界のスタチン市場の見通し、薬剤クラス別、金額（10億米ドル）、数量、2018年～2031年
  • 世界のスタチン市場の見通し、治療法別、金額（10億米ドル）、数量、2018年～2031年
  • 世界のスタチン市場の見通し、エンドユーザー別、金額（10億米ドル）、数量、2018年～2031年
  • 世界のスタチン市場の見通し、地域別、金額（10億米ドル）、数量、2018年～2031年

第6章 北米のスタチン市場の見通し、2018年～2031年

第7章 欧州のスタチン市場の見通し、2018年～2031年

第8章 アジア太平洋のスタチン市場の見通し、2018年～2031年

第9章 ラテンアメリカのスタチン市場の見通し、2018年～2031年

第10章 中東・アフリカのスタチン市場の見通し、2018年～2031年

第11章 競合情勢

  • エンドユーザー別と治療法別のヒートマップ
  • 企業の市場シェア分析、2023年
  • 競争力ダッシュボード
  • 企業プロファイル
    • Pfizer Inc.
    • AstraZeneca plc
    • Novartis International AG
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • Biocon
    • Aurobindo Pharma Ltd
    • Concord Biotech

第12章 付録

目次

North America Dominates the Market, with the United States Leading in Statin Usage

Rising Obesity and Cardiovascular Disease Cases Boost Demand for Statins Worldwide

The global statins market is on a steady growth trajectory and is expected to reach a valuation of US$ 21 billion by 2031. In 2024, the market was valued at US$ 15.4 billion.

Market Dynamics

The global demand for statins is being significantly influenced by the increasing incidence of high cholesterol and obesity cases worldwide. Lifestyle changes and sedentary habits have led to a rise in high cholesterol levels, making statins an essential solution for cholesterol management.

Statins play a crucial role in addressing high cholesterol levels that are difficult to control solely through lifestyle modifications. Additionally, awareness initiatives and advanced healthcare facilities are contributing to the growing demand for statins.

Moreover, the adoption of combination therapies that include statins alongside other cholesterol-lowering medications, such as ezetimibe, is expected to further drive the global market. Statin-ezetimibe combination therapy has shown promise in achieving near-normal lipid profiles, reducing the risk of cardiovascular diseases.

Challenges and Opportunities

While the statins market is poised for growth, challenges persist, primarily related to high manufacturing costs and the complexity of the production process. Additionally, establishing biosimilarity through rigorous analytical characterization and regulatory approval procedures remains a time-consuming and costly process.

However, increasing investments in research and development, a strong focus on improving healthcare facilities, and strategic collaborations between public and private entities are expected to provide growth opportunities for statin manufacturers.

Regional Analysis

North America is at the forefront of the global statins market and is poised to maintain its dominance throughout the forecast period. The region has a significant population suffering from cardiovascular diseases, diabetes, and obesity, driving the demand for effective cholesterol management solutions.

The United States is expected to lead the statins market in North America, with organizations like the American Heart Association and the American College of Cardiology issuing guidelines that recommend statin usage for individuals at risk of heart attacks.

Product Analysis

Statins are a class of drugs used to lower blood cholesterol levels, particularly low-density lipoprotein (LDL) cholesterol. The market for statins has witnessed steady growth, driven by increased healthcare awareness and the rising prevalence of cholesterol-related conditions.

While maintaining a healthy lifestyle can help manage cholesterol, sedentary habits have contributed to a growing need for statin therapy, particularly among the elderly population.

Key Players

Prominent players in the global statins market include: Pfizer Inc., AstraZeneca plc, Novartis International AG, GlaxoSmithKline plc, Merck & Co., Inc., Biocon, Aurobindo Pharma Ltd, and Concord Biotech.

Statins Industry Research Segmentation

By Drug Class:

  • Astrovastatins
  • Fluvastatins
  • Lovastatins
  • Pravastatins
  • Simvastatins
  • Others

By Therapeutic Treatment:

  • Cardiovascular Disorders
  • Obesity
  • Inflammatory Disorders
  • Others

By End User:

  • Hospitals
  • Clinics

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Statins Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value and Volume, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Production Output and Trade Statistics, 2018 - 2023

  • 3.1. Global Statins Production Output, by Region, Value (US$ Bn) and Volume, 2018 - 2023
    • 3.1.1. North America
    • 3.1.2. Europe
    • 3.1.3. Asia Pacific
    • 3.1.4. Latin America
    • 3.1.5. Middle East and Africa

4. Price Analysis, 2018 - 2023

  • 4.1. Global Average Price Analysis by Drug Class, 2018 - 2023
  • 4.2. Prominent Factor Affecting Statins Prices
  • 4.3. Global Average Price Analysis by Region

5. Global Statins Market Outlook, 2018 - 2031

  • 5.1. Global Statins Market Outlook, by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Astrovastatins
      • 5.1.1.2. Fluvastatins
      • 5.1.1.3. Lovastatins
      • 5.1.1.4. Pravastatins
      • 5.1.1.5. Simvastatins
      • 5.1.1.6. Others
  • 5.2. Global Statins Market Outlook, by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Cardiovascular Disorders
      • 5.2.1.2. Obesity
      • 5.2.1.3. Inflammatory Disorders
      • 5.2.1.4. Others
  • 5.3. Global Statins Market Outlook, by End User, Value (US$ Bn) and Volume, 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Hospitals
      • 5.3.1.2. Clinics
  • 5.4. Global Statins Market Outlook, by Region, Value (US$ Bn) and Volume, 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. North America
      • 5.4.1.2. Europe
      • 5.4.1.3. Asia Pacific
      • 5.4.1.4. Latin America
      • 5.4.1.5. Middle East & Africa

6. North America Statins Market Outlook, 2018 - 2031

  • 6.1. North America Statins Market Outlook, by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Astrovastatins
      • 6.1.1.2. Fluvastatins
      • 6.1.1.3. Lovastatins
      • 6.1.1.4. Pravastatins
      • 6.1.1.5. Simvastatins
      • 6.1.1.6. Others
  • 6.2. North America Statins Market Outlook, by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Cardiovascular Disorders
      • 6.2.1.2. Obesity
      • 6.2.1.3. Inflammatory Disorders
      • 6.2.1.4. Others
  • 6.3. North America Statins Market Outlook, by End User, Value (US$ Bn) and Volume, 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Hospitals
      • 6.3.1.2. Clinics
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis
  • 6.4. North America Statins Market Outlook, by Country, Value (US$ Bn) and Volume, 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. U.S. Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 6.4.1.2. U.S. Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 6.4.1.3. U.S. Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
      • 6.4.1.4. Canada Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 6.4.1.5. Canada Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 6.4.1.6. Canada Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Europe Statins Market Outlook, 2018 - 2031

  • 7.1. Europe Statins Market Outlook, by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Astrovastatins
      • 7.1.1.2. Fluvastatins
      • 7.1.1.3. Lovastatins
      • 7.1.1.4. Pravastatins
      • 7.1.1.5. Simvastatins
      • 7.1.1.6. Others
  • 7.2. Europe Statins Market Outlook, by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Cardiovascular Disorders
      • 7.2.1.2. Obesity
      • 7.2.1.3. Inflammatory Disorders
      • 7.2.1.4. Others
  • 7.3. Europe Statins Market Outlook, by End User, Value (US$ Bn) and Volume, 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Hospitals
      • 7.3.1.2. Clinics
    • 7.3.2. Attractiveness Analysis
  • 7.4. Europe Statins Market Outlook, by Country, Value (US$ Bn) and Volume, 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Germany Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 7.4.1.2. Germany Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 7.4.1.3. Germany Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
      • 7.4.1.4. U.K. Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 7.4.1.5. U.K. Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 7.4.1.6. U.K. Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
      • 7.4.1.7. France Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 7.4.1.8. France Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 7.4.1.9. France Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
      • 7.4.1.10. Italy Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 7.4.1.11. Italy Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 7.4.1.12. Italy Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
      • 7.4.1.13. Turkey Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 7.4.1.14. Turkey Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 7.4.1.15. Turkey Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
      • 7.4.1.16. Russia Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 7.4.1.17. Russia Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 7.4.1.18. Russia Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
      • 7.4.1.19. Rest of Europe Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 7.4.1.20. Rest of Europe Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 7.4.1.21. Rest of Europe Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Asia Pacific Statins Market Outlook, 2018 - 2031

  • 8.1. Asia Pacific Statins Market Outlook, by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Astrovastatins
      • 8.1.1.2. Fluvastatins
      • 8.1.1.3. Lovastatins
      • 8.1.1.4. Pravastatins
      • 8.1.1.5. Simvastatins
      • 8.1.1.6. Others
  • 8.2. Asia Pacific Statins Market Outlook, by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Cardiovascular Disorders
      • 8.2.1.2. Obesity
      • 8.2.1.3. Inflammatory Disorders
      • 8.2.1.4. Others
  • 8.3. Asia Pacific Statins Market Outlook, by End User, Value (US$ Bn) and Volume, 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Hospitals
      • 8.3.1.2. Clinics
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis
  • 8.4. Asia Pacific Statins Market Outlook, by Country, Value (US$ Bn) and Volume, 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. China Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 8.4.1.2. China Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 8.4.1.3. China Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
      • 8.4.1.4. Japan Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 8.4.1.5. Japan Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 8.4.1.6. Japan Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
      • 8.4.1.7. South Korea Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 8.4.1.8. South Korea Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 8.4.1.9. South Korea Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
      • 8.4.1.10. India Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 8.4.1.11. India Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 8.4.1.12. India Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
      • 8.4.1.13. Southeast Asia Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 8.4.1.14. Southeast Asia Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 8.4.1.15. Southeast Asia Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
      • 8.4.1.16. Rest of Asia Pacific Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 8.4.1.17. Rest of Asia Pacific Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 8.4.1.18. Rest of Asia Pacific Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Latin America Statins Market Outlook, 2018 - 2031

  • 9.1. Latin America Statins Market Outlook, by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
    • 9.1.1. Key Highlights
      • 9.1.1.1. Astrovastatins
      • 9.1.1.2. Fluvastatins
      • 9.1.1.3. Lovastatins
      • 9.1.1.4. Pravastatins
      • 9.1.1.5. Simvastatins
      • 9.1.1.6. Others
  • 9.2. Latin America Statins Market Outlook, by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
    • 9.2.1. Key Highlights
      • 9.2.1.1. Cardiovascular Disorders
      • 9.2.1.2. Obesity
      • 9.2.1.3. Inflammatory Disorders
      • 9.2.1.4. Others
  • 9.3. Latin America Statins Market Outlook, by End User, Value (US$ Bn) and Volume, 2018 - 2031
    • 9.3.1. Key Highlights
      • 9.3.1.1. Hospitals
      • 9.3.1.2. Clinics
    • 9.3.2. BPS Analysis/Market Attractiveness Analysis
  • 9.4. Latin America Statins Market Outlook, by Country, Value (US$ Bn) and Volume, 2018 - 2031
    • 9.4.1. Key Highlights
      • 9.4.1.1. Brazil Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 9.4.1.2. Brazil Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 9.4.1.3. Brazil Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
      • 9.4.1.4. Mexico Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 9.4.1.5. Mexico Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 9.4.1.6. Mexico Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
      • 9.4.1.7. Argentina Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 9.4.1.8. Argentina Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 9.4.1.9. Argentina Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
      • 9.4.1.10. Rest of Latin America Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 9.4.1.11. Rest of Latin America Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 9.4.1.12. Rest of Latin America Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
    • 9.4.2. BPS Analysis/Market Attractiveness Analysis

10. Middle East & Africa Statins Market Outlook, 2018 - 2031

  • 10.1. Middle East & Africa Statins Market Outlook, by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
    • 10.1.1. Key Highlights
      • 10.1.1.1. Astrovastatins
      • 10.1.1.2. Fluvastatins
      • 10.1.1.3. Lovastatins
      • 10.1.1.4. Pravastatins
      • 10.1.1.5. Simvastatins
      • 10.1.1.6. Others
  • 10.2. Middle East & Africa Statins Market Outlook, by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
    • 10.2.1. Key Highlights
      • 10.2.1.1. Cardiovascular Disorders
      • 10.2.1.2. Obesity
      • 10.2.1.3. Inflammatory Disorders
      • 10.2.1.4. Others
  • 10.3. Middle East & Africa Statins Market Outlook, by End User, Value (US$ Bn) and Volume, 2018 - 2031
    • 10.3.1. Key Highlights
      • 10.3.1.1. Hospitals
      • 10.3.1.2. Clinics
    • 10.3.2. BPS Analysis/Market Attractiveness Analysis
  • 10.4. Middle East & Africa Statins Market Outlook, by Country, Value (US$ Bn) and Volume, 2018 - 2031
    • 10.4.1. Key Highlights
      • 10.4.1.1. GCC Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 10.4.1.2. GCC Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 10.4.1.3. GCC Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
      • 10.4.1.4. South Africa Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 10.4.1.5. South Africa Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 10.4.1.6. South Africa Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
      • 10.4.1.7. Egypt Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 10.4.1.8. Egypt Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 10.4.1.9. Egypt Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
      • 10.4.1.10. Nigeria Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 10.4.1.11. Nigeria Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 10.4.1.12. Nigeria Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
      • 10.4.1.13. Rest of Middle East & Africa Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 10.4.1.14. Rest of Middle East & Africa Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 10.4.1.15. Rest of Middle East & Africa Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
    • 10.4.2. BPS Analysis/Market Attractiveness Analysis

11. Competitive Landscape

  • 11.1. By End User vs by Therapeutic Treatment Heatmap
  • 11.2. Company Market Share Analysis, 2023
  • 11.3. Competitive Dashboard
  • 11.4. Company Profiles
    • 11.4.1. Pfizer Inc.
      • 11.4.1.1. Company Overview
      • 11.4.1.2. Product Portfolio
      • 11.4.1.3. Financial Overview
      • 11.4.1.4. Business Strategies and Development
    • 11.4.2. AstraZeneca plc
      • 11.4.2.1. Company Overview
      • 11.4.2.2. Product Portfolio
      • 11.4.2.3. Financial Overview
      • 11.4.2.4. Business Strategies and Development
    • 11.4.3. Novartis International AG
      • 11.4.3.1. Company Overview
      • 11.4.3.2. Product Portfolio
      • 11.4.3.3. Financial Overview
      • 11.4.3.4. Business Strategies and Development
    • 11.4.4. GlaxoSmithKline plc
      • 11.4.4.1. Company Overview
      • 11.4.4.2. Product Portfolio
      • 11.4.4.3. Financial Overview
      • 11.4.4.4. Business Strategies and Development
    • 11.4.5. Merck & Co., Inc.
      • 11.4.5.1. Company Overview
      • 11.4.5.2. Product Portfolio
      • 11.4.5.3. Financial Overview
      • 11.4.5.4. Business Strategies and Development
    • 11.4.6. Biocon
      • 11.4.6.1. Company Overview
      • 11.4.6.2. Product Portfolio
      • 11.4.6.3. Financial Overview
      • 11.4.6.4. Business Strategies and Development
    • 11.4.7. Aurobindo Pharma Ltd
      • 11.4.7.1. Company Overview
      • 11.4.7.2. Product Portfolio
      • 11.4.7.3. Financial Overview
      • 11.4.7.4. Business Strategies and Development
    • 11.4.8. Concord Biotech
      • 11.4.8.1. Company Overview
      • 11.4.8.2. Product Portfolio
      • 11.4.8.3. Financial Overview
      • 11.4.8.4. Business Strategies and Development

12. Appendix

  • 12.1. Research Methodology
  • 12.2. Report Assumptions
  • 12.3. Acronyms and Abbreviations